The Use of Low Molecular Weight Heparin in Hemodiafiltration

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00756145

Enrollment

Registered

2008-09-19

Start date

2008-09-30

Completion date

2015-05-31

Last updated

2015-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

stage V, treated, hemodiafiltration

Brief summary

Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.

Interventions

PROCEDUREAt start of the session, at the inlet line

Injection of LMWH at the inlet line, at the start of the hemodiafiltration session

PROCEDURE5 minutes after the start of the session, at the inlet line

Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session

PROCEDUREAt the start of the session, at the outlet line

Injection of LMWH at the outlet line, at the start of the hemodiafiltration session

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* chronic kidney disease stade V treated with hemodiafiltration * age \>18 year * Hematocrit \> 30%

Exclusion criteria

* treatment with vitamin K antagonists * treatment with other anti-coagulants or heparin besides the heparin used during dialysis * active bleeding, infection or malignancy * heparin associated allergy * hepatic failure * trombocytopenia \< 120.000/µl

Design outcomes

Primary

Measure	Time frame
Anti-Xa activity at the end of the session	240 min after start

Secondary

Measure	Time frame	Description
ETP during the session	at start, 30 min, 120 min, 180 min and 240 min	—
Reduction ratio of urea	after 10min, 180min and 240min	—
Anti-Xa activity during the session	at start, 30 min, 120 min and 180 min	—
Visual inspection of membrane and circuit	After the hemodiafiltration session	—
pressure measurements along the circuit	during the session	inlet blood line, prefilter, transmembrane, outlet blood line
Reduction ratio of beta2microglobulin	after 10min, 180min and 240min	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026